Answers are grounded in this paper and cite their sources.
Letter addresses inaccuracies in the immunization strategy for respiratory syncytial virus in Italy, suggesting implications for policy.
Polistena et al. recently published in Infectious Diseases and Therapy a cost-effectiveness analysis of a complementary strategy combining maternal immunization with respiratory syncytial virus prefusion (RSVpreF) vaccine and monoclonal antibodies for the prevention of Respiratory Syncytial Virus (RSV) infection among Italian infants [1].While the analysis is of clear relevance, the manuscript contains an inaccurate description of the maternal RSVpreF immunization strategy in Sicily, the fourth most populous Italian region (approximately 4.8 million inhabitants).Specifically, maternal vaccination is reported as recommended between 24 and 36 weeks of gestation [1].This statement is not aligned with the Sicilian Regional Immunization Plan (SIP) 2024-2026 and with the subsequent operative decree for Sicilian health care professionals (HCPs) [2,3].According to the SIP, published in June 2024, and the subsequent Decree of the Sicilian Department of Health (September 2024), RSVpreF vaccination is recommended preferentially between 32 and 36 weeks of gestation, and only for pregnancies with an expected date of delivery between November 1 and March 31 [2,3].This distinction is not marginal, as it directly affects the target population and the estimated
No takes yet. Share an insight, caveat, or question.
Costantino et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: